logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
NNVC
NanoViricides, Inc.
1.30
15700 x 1.30
10400 x 1.37
bid
ask
-
0.01
0.76%
13050 @ 06:11 PM
1.31 +0.01 (0.77%)
Ytd15.04%
1y-9.09%
1.30
day range
1.40
0.85
52 week range
2.03
Open1.33Prev Close1.31Low1.30High1.40Mkt Cap33.18M
Vol169.63KAvg Vol445.00KEPS-0.41P/EN/AForward P/E-2.68
Beta0.97Short Ratio1.92Inst. Own9.42%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-1550-d Avg1.33200-d Avg1.271yr Est6.50

NNVC News

NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
accessnewswire.com
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 202

SHELTON, CT / ACCESS Newswire / October 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("the Com
benzinga.com
NanoViricides Updates Phase II Trial Of NV-387 Oral Gummies For Ebola Treatment In DRC; Reports Caut

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
accessnewswire.com
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a

SHELTON, CT / ACCESS Newswire / October 5, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "C

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
accessnewswire.com
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clin

SHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "
benzinga.com
Nanoviricides Q4 EPS $(0.10), Inline

Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.10) per share which met the analyst conse

Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
accessnewswire.com
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients

SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
accessnewswire.com
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces Na

SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular sessio
benzinga.com
NanoViricides Announces That Its Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Cur

Clinical trial is scheduled to start at an Ebola Treatment Center in the Ituri province."NV-387

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides
accessnewswire.com
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalitie

SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the
benzinga.com
NanoViricides Says Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugy

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
accessnewswire.com
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Data

SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the

benzinga.com
NanoViricides Advances NV-387 Measles Treatment Toward Phase II Trials Following FDA Rare Pediatric

NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical s

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
accessnewswire.com
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for

SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NY
benzinga.com
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Cri

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

NanoViricides (NYSE:NNVC) Trading Down 2.2% – Time to Sell?
defenseworld.net
NanoViricides (NYSE:NNVC) Trading Down 2.2% – Time to Sell?

NanoViricides, Inc. (NYSE: NNVC - Get Free Report)'s stock price dropped 2.2% during mid-day trading
benzinga.com
NanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibug

Under the leadership of Professor Katoto, NanoViricides, as the drug sponsor of NV-387 Oral Gummies,

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
accessnewswire.com
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the

SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Co
benzinga.com
NanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For Ebola

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
accessnewswire.com
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies

SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "C
benzinga.com
NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
accessnewswire.com
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-38

SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compa

12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's p

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
accessnewswire.com
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViric
benzinga.com
NanoVricides Applies To DRC Regulatory Agency ACOREP For Approval To Begin A Phase II Clinical Trial

NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phas
benzinga.com
NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gum

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
accessnewswire.com
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approva

SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compa

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
accessnewswire.com
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" I

SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compan
benzinga.com
Noble Capital Markets Initiates Coverage On Nanoviricides with Outperform Rating, Announces Price Ta

Noble Capital Markets analyst Robert LeBoyer initiates coverage on Nanoviricides (AMEX:NNVC) with
benzinga.com
NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Tr

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
accessnewswire.com
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Or

SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compan
benzinga.com
FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoVi

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a c

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
accessnewswire.com
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles

SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE
benzinga.com
NanoViricides Ships NV-387 Oral Gummies To The Democratic Republic of Congo Ahead Of Patient Enrollm

Clinical Trial Site preparations are being performed by our CRO in India, Om Sai Clinical Research P

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
accessnewswire.com
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"
benzinga.com
NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For C

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
accessnewswire.com
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment

SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compa
benzinga.com
NanoViricides Proposes Phase II Clinical Study Of NV-387 Oral Gummies To Congo To Treat Current Bund

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
accessnewswire.com
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial

SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compan
benzinga.com
NanoViricides Files Prospectus For Offering $50M Mixed Shelf

https://www.sec.gov/Archives/edgar/data/1379006/000110465926071007/tm2616485d1_s3.htm

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares ro
benzinga.com
NanoViricides Prices Sale Of 1,333,334 Shares And Warrants For Gross Proceeds Of ~$2M

NanoViricides, Inc. (NYSE:NNVC) ("NanoViricides" or the "Company"), a clinical stage
benzinga.com
NanoViricides' Clinical Stage, Broad-Spectrum, Antiviral Drug NV-387 Granted Orphan Drug Designation

NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical s
benzinga.com
NanoViricides Granted FDA Orphan Drug Designation Status For Treatment Of The Measles Virus

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1140226

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after th
benzinga.com
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after g